SITE Centers Key Executives
This section highlights SITE Centers's key executives, including their titles and compensation details.
Find Contacts at SITE Centers
(Showing 0 of )
SITE Centers Earnings
This section highlights SITE Centers's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2024 | 2024-07-30 | $0.96 | $1.08 |
| Read Transcript | Q1 | 2024 | 2024-04-30 | $0.96 | $1.12 |
| Read Transcript | Q4 | 2023 | 2024-02-13 | $1.04 | $1.04 |
| Read Transcript | Q3 | 2023 | 2023-10-30 | $1.12 | $1.32 |
| Read Transcript | Q2 | 2023 | 2023-07-25 | $1.12 | $1.16 |
| Read Transcript | Q1 | 2023 | 2023-04-25 | $1.12 | $1.20 |
SITE Centers is an owner and manager of open-air shopping centers that provide a highly-compelling shopping experience and merchandise mix for retail partners and consumers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.
$13.15
Stock Price
$689.46M
Market Cap
172
Employees
Beachwood, OH
Location
Financial Statements
Access annual & quarterly financial statements for SITE Centers, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $277.47M | $546.27M | $540.81M | $492.34M | $416.76M |
| Cost of Revenue | $95.66M | $165.72M | $169.98M | $152.79M | $138.40M |
| Gross Profit | $181.80M | $380.55M | $370.82M | $339.56M | $278.36M |
| Gross Profit Ratio | 65.52% | 69.70% | 68.57% | 69.00% | 66.79% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $47.08M | $50.87M | $46.56M | $55.05M | $52.88M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $47.08M | $50.87M | $46.56M | $55.05M | $52.88M |
| Other Expenses | $134.72M | $- | $203.55M | $185.77M | $170.67M |
| Operating Expenses | $181.80M | $45.87M | $250.11M | $240.82M | $223.55M |
| Cost and Expenses | $277.47M | $430.46M | $420.09M | $393.61M | $361.95M |
| Interest Income | $31.62M | $- | $- | $- | $11.89M |
| Interest Expense | $59.46M | $82.00M | $77.69M | $77.03M | $77.60M |
| Depreciation and Amortization | $130.90M | $212.46M | $203.55M | $185.77M | $170.67M |
| EBITDA | $716.89M | $339.27M | $361.16M | $372.32M | $263.06M |
| EBITDA Ratio | 258.37% | 62.11% | 66.78% | 75.62% | 63.12% |
| Operating Income | $525.76M | $339.27M | $157.61M | $186.55M | $92.39M |
| Operating Income Ratio | 189.49% | 62.11% | 29.14% | 37.89% | 22.17% |
| Total Other Income Expenses Net | $761.00K | $-71.50M | $-188.46M | $-12.29M | $-62.36M |
| Income Before Tax | $526.52M | $267.77M | $169.61M | $126.97M | $37.72M |
| Income Before Tax Ratio | 189.76% | 49.02% | 31.36% | 25.79% | 9.05% |
| Income Tax Expense | $761.00K | $2.04M | $816.00K | $1.55M | $1.13M |
| Net Income | $531.82M | $265.70M | $168.72M | $124.94M | $35.72M |
| Net Income Ratio | 191.67% | 48.64% | 31.20% | 25.38% | 8.57% |
| EPS | $10.49 | $4.85 | $2.96 | $2.04 | $0.74 |
| EPS Diluted | $10.46 | $4.85 | $2.92 | $2.04 | $0.74 |
| Weighted Average Shares Outstanding | 52.40M | 52.36M | 53.25M | 52.00M | 48.33M |
| Weighted Average Shares Outstanding Diluted | 52.55M | 52.41M | 53.47M | 52.29M | 48.44M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $-51.06M | $90.76M | $115.67M | $122.09M | $124.67M | $143.09M | $136.38M | $136.83M | $136.43M | $136.19M | $140.68M | $131.06M | $124.56M | $121.08M | $135.47M | $119.99M | $108.47M | $95.94M | $98.26M | $129.31M |
| Cost of Revenue | $-5.37M | $62.61M | $35.40M | $37.28M | $38.22M | $41.53M | $42.76M | $43.22M | $42.23M | $42.74M | $42.90M | $42.12M | $36.23M | $37.72M | $38.96M | $39.88M | $36.08M | $32.32M | $33.87M | $36.14M |
| Gross Profit | $-45.69M | $28.16M | $80.27M | $84.81M | $86.45M | $101.56M | $93.63M | $93.61M | $94.21M | $93.45M | $97.78M | $88.94M | $88.33M | $83.36M | $96.51M | $80.11M | $72.39M | $63.63M | $64.39M | $93.17M |
| Gross Profit Ratio | 89.48% | 31.00% | 69.40% | 69.50% | 69.30% | 71.00% | 68.70% | 68.40% | 69.10% | 68.60% | 69.50% | 67.90% | 70.90% | 68.80% | 71.20% | 66.80% | 66.74% | 66.32% | 65.53% | 72.05% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $8.18M | $15.11M | $12.71M | $11.07M | $14.93M | $11.26M | $11.10M | $10.64M | $12.16M | $10.80M | $11.35M | $12.25M | $13.51M | $11.73M | $12.43M | $17.39M | $14.34M | $13.66M | $13.50M | $11.38M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $2.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $8.18M | $15.11M | $12.71M | $11.07M | $14.93M | $11.26M | $11.10M | $10.64M | $12.16M | $10.80M | $11.35M | $12.25M | $13.51M | $11.73M | $12.43M | $17.39M | $14.34M | $13.66M | $13.50M | $11.38M |
| Other Expenses | $-53.87M | $- | $40.44M | $43.15M | $46.92M | $-690.00K | $59.06M | $54.02M | $50.98M | $51.18M | $51.02M | $50.36M | $48.32M | $13.36M | $-324.00K | $8.15M | $9.43M | $13.15M | $3.82M | $-18.06M |
| Operating Expenses | $-45.69M | $15.11M | $53.15M | $54.22M | $61.86M | $64.08M | $70.16M | $64.66M | $63.14M | $61.98M | $62.37M | $62.62M | $61.83M | $56.40M | $59.64M | $62.95M | $59.99M | $54.81M | $54.38M | $54.37M |
| Cost and Expenses | $-51.06M | $77.62M | $88.55M | $91.50M | $100.08M | $105.61M | $112.92M | $107.88M | $105.37M | $104.72M | $105.28M | $104.73M | $98.06M | $94.12M | $98.60M | $102.83M | $96.08M | $87.13M | $88.24M | $90.51M |
| Interest Income | $1.78M | $14.00M | $8.55M | $7.29M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.41M | $3.44M | $3.55M | $3.48M |
| Interest Expense | $5.42M | $16.71M | $18.43M | $18.91M | $20.01M | $21.15M | $20.92M | $19.92M | $20.39M | $20.14M | $18.91M | $18.26M | $18.83M | $19.34M | $19.14M | $19.39M | $19.12M | $18.09M | $19.81M | $20.59M |
| Depreciation and Amortization | $13.06M | $34.25M | $40.44M | $43.15M | $46.92M | $52.82M | $58.70M | $54.02M | $50.98M | $51.18M | $51.02M | $50.36M | $32.99M | $44.67M | $47.22M | $45.56M | $45.66M | $41.15M | $40.87M | $42.99M |
| EBITDA | $6.63M | $47.30M | $67.62M | $74.50M | $76.42M | $92.46M | $87.92M | $85.50M | $84.16M | $110.72M | $86.66M | $79.61M | $124.60M | $86.75M | $87.84M | $75.25M | $69.67M | $59.71M | $58.62M | $83.81M |
| EBITDA Ratio | -12.98% | 52.11% | 257.10% | 31.75% | 212.24% | 64.16% | 64.47% | 62.48% | 61.68% | 81.30% | 61.60% | 60.75% | 97.40% | 71.70% | 65.41% | 62.71% | 64.07% | 69.63% | 57.75% | 53.67% |
| Operating Income | $- | $13.05M | $27.12M | $30.59M | $24.59M | $101.56M | $29.22M | $31.48M | $33.17M | $59.55M | $35.64M | $29.25M | $88.33M | $83.36M | $41.49M | $80.11M | $72.39M | $63.63M | $64.39M | $55.15M |
| Operating Income Ratio | 0.00% | 14.37% | 23.45% | 25.05% | 19.73% | 70.98% | 21.43% | 23.01% | 24.32% | 43.72% | 25.33% | 22.32% | 70.91% | 68.85% | 30.63% | 66.76% | 66.74% | 66.32% | 65.53% | 42.65% |
| Total Other Income Expenses Net | $-11.85M | $310.11M | $170.91M | $-10.75M | $173.07M | $-43.58M | $-16.96M | $-15.30M | $-4.97M | $-40.11M | $-27.05M | $-15.38M | $-28.75M | $-11.96M | $-14.39M | $26.16M | $-22.59M | $-10.74M | $-23.39M | $-3.94M |
| Income Before Tax | $-11.85M | $323.15M | $238.53M | $-23.30M | $197.66M | $48.88M | $5.35M | $15.52M | $28.17M | $66.47M | $60.76M | $14.21M | $59.58M | $28.36M | $22.48M | $16.55M | $-766.00K | $7.69M | $-4.06M | $34.86M |
| Income Before Tax Ratio | 23.21% | 356.04% | 206.21% | -19.08% | 158.55% | 34.16% | 3.92% | 11.34% | 20.65% | 48.81% | 43.19% | 10.84% | 47.84% | 23.42% | 16.59% | 13.79% | -0.71% | 8.01% | -4.13% | 26.96% |
| Income Tax Expense | $29.00K | $199.00K | $281.00K | $252.00K | $1.23M | $236.00K | $26.68M | $213.00K | $-47.00K | $258.00K | $353.00K | $252.00K | $493.00K | $202.00K | $490.00K | $365.00K | $272.00K | $284.00K | $342.00K | $233.00K |
| Net Income | $-5.82M | $322.95M | $238.25M | $-23.55M | $196.42M | $48.64M | $-21.33M | $15.28M | $28.20M | $66.19M | $60.39M | $13.94M | $58.99M | $28.06M | $21.87M | $16.01M | $-1.28M | $7.29M | $-4.61M | $34.33M |
| Net Income Ratio | 11.40% | 355.82% | 205.97% | -19.29% | 157.56% | 33.99% | -15.64% | 11.17% | 20.67% | 48.60% | 42.93% | 10.63% | 47.36% | 23.18% | 16.14% | 13.34% | -1.18% | 7.60% | -4.69% | 26.55% |
| EPS | $-0.26 | $6.09 | $4.48 | $-0.45 | $3.68 | $0.87 | $-0.41 | $0.24 | $0.48 | $1.20 | $1.08 | $0.20 | $1.08 | $0.48 | $0.41 | $0.32 | $-0.03 | $0.15 | $-0.10 | $0.60 |
| EPS Diluted | $-0.26 | $6.07 | $4.44 | $-0.45 | $3.68 | $0.87 | $-0.41 | $0.24 | $0.48 | $1.20 | $1.08 | $0.20 | $1.04 | $0.48 | $0.41 | $0.32 | $-0.03 | $0.15 | $-0.10 | $0.60 |
| Weighted Average Shares Outstanding | 52.40M | 52.40M | 52.39M | 52.35M | 52.33M | 52.32M | 52.32M | 52.49M | 53.04M | 53.46M | 53.47M | 53.03M | 52.81M | 52.76M | 52.76M | 49.63M | 48.31M | 48.30M | 48.29M | 48.43M |
| Weighted Average Shares Outstanding Diluted | 52.55M | 52.55M | 52.83M | 52.35M | 52.35M | 52.35M | 52.36M | 52.60M | 53.21M | 53.58M | 53.73M | 53.30M | 53.09M | 53.05M | 52.97M | 49.86M | 48.31M | 48.34M | 48.29M | 48.43M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $54.59M | $551.97M | $20.25M | $41.81M | $69.74M |
| Short Term Investments | $- | $- | $44.61M | $- | $- |
| Cash and Short Term Investments | $54.59M | $551.97M | $20.25M | $41.81M | $69.74M |
| Net Receivables | $25.44M | $65.62M | $63.93M | $61.38M | $73.52M |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $- | $49.62M | $19.01M | $12.96M | $15.86M |
| Total Current Assets | $80.03M | $667.22M | $85.14M | $104.63M | $147.93M |
| Property Plant Equipment Net | $15.82M | $17.37M | $18.20M | $19.05M | $20.60M |
| Goodwill | $- | $- | $18.20M | $- | $- |
| Intangible Assets | $12.94M | $68.99M | $87.75M | $113.11M | $111.02M |
| Goodwill and Intangible Assets | $12.94M | $68.99M | $105.94M | $113.11M | $111.02M |
| Long Term Investments | $30.43M | $39.37M | $44.61M | $64.63M | $267.33M |
| Tax Assets | $- | $- | $- | $3.65B | $3.54B |
| Other Non-Current Assets | $773.20M | $3.27B | $3.79B | $17.37M | $19.67M |
| Total Non-Current Assets | $832.39M | $3.39B | $3.96B | $3.86B | $3.96B |
| Other Assets | $21.18M | $- | $- | $- | $- |
| Total Assets | $933.60M | $4.06B | $4.05B | $3.97B | $4.11B |
| Account Payables | $115.48M | $112.52M | $214.99M | $218.78M | $215.11M |
| Short Term Debt | $- | $684.00K | $- | $- | $135.00M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $- | $146.33M | $-67.21M | $-69.94M | $-335.26M |
| Total Current Liabilities | $115.48M | $259.53M | $30.39M | $28.24M | $14.84M |
| Long Term Debt | $301.37M | $1.63B | $1.71B | $1.68B | $1.93B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $79.47M | $97.60M | $98.18M | $- |
| Total Non-Current Liabilities | $301.37M | $1.71B | $1.92B | $1.90B | $2.15B |
| Other Liabilities | $- | $-78.78M | $- | $- | $- |
| Total Liabilities | $416.86M | $1.89B | $1.95B | $1.92B | $2.16B |
| Preferred Stock | $- | $175.00M | $175.00M | $175.00M | $325.00M |
| Common Stock | $5.25M | $21.44M | $21.44M | $21.13M | $19.40M |
| Retained Earnings | $-3.47B | $-3.93B | $-4.05B | $-4.09B | $-4.10B |
| Accumulated Other Comprehensive Income Loss | $5.47M | $6.12M | $9.04M | $- | $-2.68M |
| Other Total Stockholders Equity | $3.98B | $5.91B | $5.93B | $5.93B | $5.70B |
| Total Stockholders Equity | $516.74M | $2.18B | $2.09B | $2.04B | $1.94B |
| Total Equity | $516.74M | $2.18B | $2.09B | $2.04B | $1.94B |
| Total Liabilities and Stockholders Equity | $933.60M | $4.06B | $4.05B | $3.97B | $4.11B |
| Minority Interest | $- | $- | $5.79M | $5.79M | $3.31M |
| Total Liabilities and Total Equity | $933.60M | $4.06B | $4.05B | $3.97B | $4.11B |
| Total Investments | $30.43M | $39.37M | $89.22M | $64.63M | $267.33M |
| Total Debt | $301.37M | $1.63B | $1.71B | $1.68B | $1.93B |
| Net Debt | $246.78M | $1.07B | $1.69B | $1.64B | $1.86B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $54.59M | $1.06B | $1.18B | $551.28M | $551.97M | $26.56M | $28.04M | $25.03M | $20.25M | $20.88M | $38.53M | $17.19M | $41.81M | $61.92M | $57.95M | $190.83M | $69.74M | $57.22M | $128.49M | $514.26M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $44.61M | $46.00M | $53.02M | $46.00M | $- | $- | $- | $- | $- | $96.13M | $89.05M | $- |
| Cash and Short Term Investments | $54.59M | $1.06B | $1.18B | $551.28M | $551.97M | $26.56M | $28.04M | $25.03M | $20.25M | $20.88M | $38.53M | $17.19M | $41.81M | $61.92M | $57.95M | $190.83M | $69.74M | $57.22M | $128.49M | $514.26M |
| Net Receivables | $27.21M | $38.84M | $48.16M | $57.16M | $65.62M | $65.19M | $61.38M | $59.86M | $63.93M | $59.45M | $54.83M | $52.48M | $61.38M | $59.91M | $61.98M | $63.76M | $73.52M | $79.21M | $81.18M | $56.44M |
| Inventory | $- | $- | $10.65M | $15.70M | $7.96M | $- | $- | $- | $- | $-12.83M | $- | $-17.57M | $-11.52M | $-13.95M | $- | $-18.25M | $-11.18M | $-11.27M | $-12.72M | $- |
| Other Current Assets | $19.41M | $34.80M | $45.10M | $62.57M | $57.59M | $61.74M | $22.99M | $28.34M | $19.01M | $24.85M | $14.51M | $19.60M | $12.96M | $17.37M | $15.94M | $21.12M | $15.86M | $11.56M | $12.92M | $14.72M |
| Total Current Assets | $101.21M | $1.14B | $1.26B | $655.31M | $667.22M | $128.45M | $89.97M | $85.32M | $85.14M | $83.45M | $107.87M | $71.69M | $104.63M | $125.25M | $135.87M | $257.46M | $147.93M | $232.85M | $298.92M | $585.42M |
| Property Plant Equipment Net | $15.82M | $16.09M | $16.35M | $17.11M | $17.37M | $- | $17.63M | $17.91M | $18.20M | $17.80M | $18.19M | $18.62M | $19.05M | $19.47M | $19.62M | $20.05M | $20.60M | $21.02M | $21.59M | $22.01M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $17.91M | $18.20M | $17.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $12.94M | $77.02M | $76.07M | $61.91M | $68.99M | $92.13M | $81.35M | $83.54M | $87.75M | $98.55M | $104.11M | $120.39M | $113.11M | $97.47M | $81.45M | $104.13M | $111.02M | $67.77M | $71.74M | $54.02M |
| Goodwill and Intangible Assets | $12.94M | $77.02M | $76.07M | $61.91M | $68.99M | $92.13M | $81.35M | $101.45M | $105.94M | $116.35M | $104.11M | $120.39M | $113.11M | $97.47M | $81.45M | $104.13M | $111.02M | $67.77M | $71.74M | $54.02M |
| Long Term Investments | $30.43M | $32.18M | $32.58M | $38.61M | $39.37M | $40.83M | $40.56M | $45.58M | $44.61M | $46.00M | $53.02M | $57.05M | $64.63M | $262.81M | $265.17M | $266.02M | $267.33M | $269.89M | $274.54M | $369.09M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $3.80B | $- | $- | $- | $- | $- | $- | $3.53B | $3.55B | $3.50B | $3.54B | $3.33B | $3.36B | $3.41B |
| Other Non-Current Assets | $773.20M | $1.87B | $2.66B | $3.12B | $3.27B | $3.76B | $30.41M | $3.80B | $3.79B | $3.93B | $3.92B | $3.78B | $3.67B | $20.38M | $1.89M | $26.82M | $19.67M | $20.27M | $22.27M | $3.33M |
| Total Non-Current Assets | $832.39M | $1.99B | $2.78B | $3.24B | $3.39B | $3.90B | $3.97B | $3.97B | $3.96B | $4.11B | $4.10B | $3.98B | $3.86B | $3.93B | $3.92B | $3.92B | $3.96B | $3.71B | $3.75B | $3.86B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $933.60M | $3.13B | $4.05B | $3.89B | $4.06B | $4.03B | $4.06B | $4.05B | $4.05B | $4.20B | $4.20B | $4.05B | $3.97B | $4.05B | $4.05B | $4.18B | $4.11B | $3.94B | $4.05B | $4.45B |
| Account Payables | $115.48M | $171.54M | $167.66M | $173.24M | $195.73M | $208.15M | $210.93M | $195.82M | $214.99M | $226.95M | $215.14M | $206.34M | $218.78M | $213.02M | $209.76M | $195.05M | $215.11M | $203.03M | $196.75M | $186.84M |
| Short Term Debt | $- | $- | $- | $- | $684.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $135.00M | $175.00M | $285.00M | $645.00M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $-684.00K | $- | $-210.93M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-215.11M | $-203.03M | $-196.75M | $- |
| Other Current Liabilities | $- | $2.79M | $-7.81M | $-13.08M | $-15.66M | $-43.05M | $-5.84M | $-165.74M | $-67.21M | $-196.42M | $30.70M | $-175.65M | $-69.94M | $-184.77M | $28.25M | $-166.79M | $-335.26M | $-213.07M | $-324.30M | $-646.65M |
| Total Current Liabilities | $115.48M | $174.33M | $197.84M | $203.40M | $259.53M | $165.10M | $205.08M | $30.08M | $30.39M | $30.53M | $245.84M | $30.69M | $28.24M | $28.25M | $238.00M | $28.26M | $14.84M | $5.13M | $5.13M | $230.89M |
| Long Term Debt | $301.37M | $300.84M | $1.51B | $1.57B | $1.66B | $1.74B | $1.80B | $1.78B | $1.71B | $1.82B | $1.87B | $1.76B | $1.68B | $1.79B | $1.80B | $1.78B | $1.93B | $1.78B | $1.89B | $2.25B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $37.98M | $43.24M | $46.10M | $73.15M | $57.84M | $- | $97.60M | $- | $- | $63.37M | $98.18M | $54.80M | $- | $- | $- | $43.20M | $44.44M | $45.70M |
| Total Non-Current Liabilities | $301.37M | $300.84M | $1.51B | $1.57B | $1.63B | $1.81B | $1.83B | $1.98B | $1.92B | $2.05B | $1.87B | $1.96B | $1.90B | $2.01B | $1.80B | $1.98B | $2.15B | $1.98B | $2.08B | $2.25B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $416.86M | $475.17M | $1.71B | $1.77B | $1.89B | $1.98B | $2.04B | $2.01B | $1.95B | $2.08B | $2.11B | $2.00B | $1.92B | $2.03B | $2.04B | $2.00B | $2.16B | $1.99B | $2.09B | $2.48B |
| Preferred Stock | $- | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $175.00M | $325.00M | $325.00M | $325.00M | $325.00M | $325.00M |
| Common Stock | $5.25M | $5.25M | $21.44M | $21.44M | $21.44M | $21.44M | $21.44M | $21.44M | $21.44M | $21.44M | $21.44M | $21.42M | $21.13M | $21.11M | $21.10M | $21.10M | $19.40M | $19.40M | $19.40M | $19.40M |
| Retained Earnings | $-3.47B | $-3.46B | $-3.78B | $-3.99B | $-3.93B | $-4.07B | $-4.09B | $-4.06B | $-4.05B | $-4.04B | $-4.08B | $-4.11B | $-4.09B | $-4.12B | $-4.12B | $-4.11B | $-4.10B | $-4.08B | $-4.09B | $-4.08B |
| Accumulated Other Comprehensive Income Loss | $5.47M | $6.11M | $8.57M | $8.72M | $6.12M | $12.05M | $10.12M | $5.84M | $9.04M | $9.78M | $- | $- | $- | $- | $- | $- | $-2.68M | $-3.73M | $188.00K | $-104.00K |
| Other Total Stockholders Equity | $3.98B | $5.93B | $5.91B | $5.91B | $5.91B | $5.91B | $5.90B | $5.90B | $5.93B | $5.95B | $5.97B | $5.96B | $5.93B | $5.94B | $5.94B | $5.93B | $5.69B | $5.70B | $5.70B | $5.70B |
| Total Stockholders Equity | $516.74M | $2.65B | $2.33B | $2.12B | $2.18B | $2.05B | $2.02B | $2.04B | $2.09B | $2.11B | $2.08B | $2.05B | $2.04B | $2.01B | $2.01B | $2.17B | $1.94B | $1.96B | $1.96B | $1.96B |
| Total Equity | $516.74M | $2.65B | $2.33B | $2.12B | $2.18B | $2.05B | $2.02B | $2.05B | $2.09B | $2.12B | $2.09B | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $933.60M | $3.13B | $4.05B | $3.89B | $4.06B | $4.03B | $4.06B | $4.05B | $4.05B | $4.20B | $4.20B | $4.05B | $3.97B | $4.05B | $4.05B | $4.18B | $4.11B | $3.94B | $4.05B | $4.45B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $5.79M | $5.79M | $5.79M | $5.79M | $5.79M | $5.79M | $3.65M | $3.57M | $3.47M | $3.31M | $3.24M | $3.29M | $3.08M |
| Total Liabilities and Total Equity | $933.60M | $3.13B | $4.05B | $3.89B | $4.06B | $4.03B | $4.06B | $4.05B | $4.05B | $4.20B | $4.20B | $4.05B | $3.97B | $4.05B | $4.05B | $4.18B | $4.11B | $3.94B | $4.05B | $4.45B |
| Total Investments | $30.43M | $32.18M | $32.58M | $38.61M | $39.37M | $40.83M | $40.56M | $45.58M | $89.22M | $92.00M | $106.05M | $103.05M | $64.63M | $262.81M | $265.17M | $266.02M | $267.33M | $366.02M | $363.59M | $369.09M |
| Total Debt | $301.37M | $300.84M | $1.51B | $1.57B | $1.63B | $1.83B | $1.89B | $1.78B | $1.71B | $1.82B | $1.87B | $1.76B | $1.68B | $1.79B | $1.80B | $1.78B | $1.93B | $1.78B | $1.89B | $2.25B |
| Net Debt | $246.78M | $-762.25M | $332.34M | $1.01B | $1.07B | $1.80B | $1.86B | $1.76B | $1.69B | $1.80B | $1.83B | $1.74B | $1.64B | $1.73B | $1.74B | $1.59B | $1.86B | $1.72B | $1.76B | $1.73B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $531.82M | $265.72M | $168.79M | $125.42M | $36.59M |
| Depreciation and Amortization | $130.90M | $212.46M | $203.55M | $185.77M | $170.67M |
| Deferred Income Tax | $- | $- | $- | $-60.17M | $-3.63M |
| Stock Based Compensation | $6.83M | $7.63M | $7.22M | $13.53M | $8.80M |
| Change in Working Capital | $-36.30M | $-20.55M | $-7.79M | $13.66M | $-23.84M |
| Accounts Receivables | $6.00M | $-7.47M | $-5.53M | $15.87M | $-11.65M |
| Inventory | $- | $- | $- | $-13.40K | $- |
| Accounts Payables | $- | $-3.04M | $-125.00K | $13.40K | $- |
| Other Working Capital | $-42.30M | $-10.05M | $-2.14M | $-2.21M | $-12.18M |
| Other Non Cash Items | $-521.22M | $-226.73M | $-114.50M | $4.31M | $1.58M |
| Net Cash Provided by Operating Activities | $112.04M | $238.53M | $257.26M | $282.51M | $190.17M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $3.26M | $39.08M | $-4.60M | $139.37M |
| Purchases of Investments | $- | $- | $-5.93M | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $1.84B | $556.64M | $-200.71M | $79.05M | $-36.90M |
| Net Cash Used for Investing Activities | $1.84B | $559.90M | $-167.56M | $74.45M | $102.48M |
| Debt Repayment | $-1.32B | $-81.35M | $28.79M | $-350.29M | $-128.45M |
| Common Stock Issued | $- | $- | $36.72M | $224.97M | $- |
| Common Stock Repurchased | $-4.77M | $-28.35M | $-42.26M | $- | $-7.50M |
| Dividends Paid | $-128.06M | $-120.52M | $-120.02M | $-99.54M | $-98.35M |
| Other Financing Activities | $-1.00B | $-20.41M | $-14.98M | $-157.22M | $-3.07M |
| Net Cash Used Provided by Financing Activities | $-2.46B | $-250.62M | $-111.74M | $-380.98M | $-237.36M |
| Effect of Forex Changes on Cash | $- | $- | $- | $-1.00K | $-4.00K |
| Net Change in Cash | $-501.37M | $547.82M | $-22.04M | $-31.16M | $55.28M |
| Cash at End of Period | $67.67M | $569.03M | $21.21M | $43.25M | $74.41M |
| Cash at Beginning of Period | $569.03M | $21.21M | $43.25M | $74.41M | $19.13M |
| Operating Cash Flow | $112.04M | $238.53M | $257.26M | $282.51M | $190.17M |
| Capital Expenditure | $- | $- | $- | $- | $- |
| Free Cash Flow | $112.04M | $238.53M | $257.26M | $282.51M | $190.17M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-5.82M | $322.95M | $238.25M | $-23.55M | $196.42M | $48.64M | $5.35M | $15.30M | $28.21M | $66.21M | $60.41M | $13.96M | $59.09M | $28.16M | $21.99M | $16.18M | $-1.04M | $7.40M | $-4.40M | $34.63M |
| Depreciation and Amortization | $13.06M | $34.25M | $40.44M | $43.15M | $46.92M | $52.82M | $58.70M | $54.02M | $50.98M | $51.18M | $51.02M | $50.36M | $48.32M | $44.67M | $47.22M | $45.56M | $45.66M | $41.15M | $40.87M | $42.99M |
| Deferred Income Tax | $- | $- | $- | $- | $4.34M | $- | $-4.34M | $- | $- | $- | $- | $- | $- | $-6.75M | $-4.00M | $-10.21M | $5.12M | $-3.55M | $6.68M | $-11.88M |
| Stock Based Compensation | $327.00K | $2.22M | $2.26M | $2.03M | $2.10M | $1.90M | $1.88M | $1.76M | $1.79M | $1.80M | $1.80M | $1.82M | $1.83M | $2.07M | $1.93M | $7.69M | $3.13M | $2.90M | $2.75M | $18.00K |
| Change in Working Capital | $-39.69M | $11.29M | $11.85M | $-19.75M | $-10.24M | $-7.55M | $21.95M | $-24.71M | $-14.34M | $7.12M | $14.20M | $-14.77M | $-5.99M | $3.37M | $20.41M | $-4.13M | $10.35M | $5.13M | $-10.91M | $-28.40M |
| Accounts Receivables | $-579.00K | $-873.00K | $-333.00K | $7.79M | $-6.29M | $-4.43M | $-1.57M | $4.82M | $-5.62M | $-5.01M | $-1.71M | $6.82M | $-2.52M | $2.12M | $2.63M | $13.64M | $6.85M | $2.06M | $-24.74M | $4.18M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $14.26M | $2.99M | $- | $- | $- | $11.59M | $- | $- | $664.00K |
| Accounts Payables | $- | $16.76M | $12.71M | $-15.64M | $-10.36M | $8.95M | $- | $-16.20M | $-6.49M | $8.03M | $-1.66M | $-14.26M | $-2.99M | $- | $- | $-13.05M | $-7.75M | $- | $- | $-19.29M |
| Other Working Capital | $-39.11M | $-4.60M | $12.18M | $-27.54M | $-3.95M | $-3.12M | $23.52M | $-13.32M | $-2.23M | $4.11M | $17.56M | $-21.58M | $-3.47M | $1.25M | $17.78M | $-4.72M | $-334.00K | $3.07M | $13.82M | $-13.95M |
| Other Non Cash Items | $965.00K | $-333.96M | $-226.30M | $38.07M | $-188.73M | $-30.55M | $1.09M | $-4.20M | $-14.87M | $-52.94M | $-45.35M | $-1.35M | $-38.11M | $1.09M | $1.10M | $1.01M | $1.02M | $1.03M | $1.03M | $-1.51M |
| Net Cash Provided by Operating Activities | $-31.16M | $36.76M | $66.49M | $39.95M | $46.48M | $65.25M | $84.63M | $42.17M | $51.78M | $73.38M | $82.09M | $50.02M | $65.15M | $72.61M | $88.65M | $56.11M | $64.24M | $54.07M | $36.02M | $35.85M |
| Investments in Property Plant and Equipment | $- | $-18.45M | $-19.61M | $-19.81M | $-28.60M | $-29.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $-52.00K | $-35.00K | $-872.00K | $-44.00K | $-27.00K | $-32.00K | $-30.00K | $3.35M | $-24.00K | $-23.00K | $39.19M | $-55.00K | $-20.42M | $-94.00K | $-61.00K | $15.97M | $-862.00K | $-60.00K | $-138.00K | $140.43M |
| Purchases of Investments | $- | $-35.00K | $-872.00K | $-44.00K | $-27.00K | $-32.00K | $- | $- | $5.41M | $-5.87M | $-5.47M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $731.63M | $116.06M | $709.40M | $112.29M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-6.01M | $1.14B | $648.74M | $78.18M | $617.44M | $55.48M | $-62.10M | $-54.17M | $109.89M | $12.00M | $-168.16M | $-154.45M | $159.60M | $-33.08M | $-42.04M | $-5.44M | $970.00K | $-9.49M | $-17.08M | $-11.29M |
| Net Cash Used for Investing Activities | $-6.06M | $1.12B | $647.87M | $78.14M | $617.41M | $55.44M | $-62.13M | $-50.83M | $115.28M | $6.11M | $-134.45M | $-154.50M | $139.18M | $-33.17M | $-42.10M | $10.54M | $108.00K | $-9.55M | $-17.22M | $129.14M |
| Debt Repayment | $-138.00K | $-1.21B | $-51.86M | $-60.89M | $-128.06M | $-55.60M | $12.48M | $74.69M | $-44.43M | $-45.44M | $109.56M | $80.30M | $-189.67M | $-6.46M | $-589.00K | $-153.56M | $-40.65M | $-110.40M | $-360.39M | $383.00M |
| Common Stock Issued | $- | $- | $- | $- | $-95.15M | $- | $- | $- | $-7.00K | $-126.00K | $3.08M | $33.78M | $-192.00K | $-164.00K | $-199.00K | $225.53M | $- | $- | $- | $- |
| Common Stock Repurchased | $-175.03M | $-2.12M | $-62.00K | $-2.59M | $6.00K | $-380.00K | $-1.74M | $-31.41M | $-22.26M | $-20.00M | $5.42M | $-5.42M | $- | $- | $- | $-4.48M | $-1.47M | $-6.00K | $-1.00K | $-7.50M |
| Dividends Paid | $-4.06M | $-30.14M | $-30.13M | $-63.73M | $-30.07M | $-30.05M | $-30.05M | $-30.35M | $-30.49M | $-30.66M | $-30.66M | $-28.21M | $-28.22M | $-28.22M | $-28.26M | $-14.84M | $-5.13M | $-5.13M | $-44.05M | $-44.04M |
| Other Financing Activities | $-975.05M | $-20.10M | $-3.51M | $-5.78M | $1.73M | $- | $-63.00K | $-4.82M | $-72.67M | $-438.00K | $-13.07M | $-17.00K | $-8.34M | $-407.00K | $-150.05M | $-4.48M | $-168.00K | $-166.00K | $-29.00K | $-1.23M |
| Net Cash Used Provided by Financing Activities | $-979.25M | $-1.26B | $-85.50M | $-130.40M | $-158.12M | $-86.03M | $-19.37M | $12.90M | $-169.85M | $-96.67M | $74.33M | $80.44M | $-219.28M | $-35.25M | $-179.10M | $52.64M | $-47.42M | $-115.70M | $-404.47M | $330.23M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-21.01M | $- | $21.01M | $- | $- | $- | $- | $- | $1.00K | $- | $- | $-1.00K | $-21.00K | $13.00K | $-4.00K | $8.00K |
| Net Change in Cash | $-1.02B | $-101.45M | $628.86M | $-12.31M | $505.77M | $34.67M | $3.13M | $4.25M | $-2.79M | $-17.18M | $21.97M | $-24.04M | $-22.09M | $4.19M | $-132.55M | $119.29M | $16.90M | $-71.17M | $-385.68M | $495.23M |
| Cash at End of Period | $67.67M | $1.08B | $1.19B | $556.72M | $569.03M | $63.26M | $28.59M | $25.46M | $21.21M | $24.00M | $41.18M | $19.21M | $43.25M | $65.34M | $61.15M | $193.70M | $74.41M | $57.51M | $128.68M | $514.36M |
| Cash at Beginning of Period | $1.08B | $1.19B | $556.72M | $569.03M | $63.26M | $28.59M | $25.46M | $21.21M | $24.00M | $41.18M | $19.21M | $43.25M | $65.34M | $61.15M | $193.70M | $74.41M | $57.51M | $128.68M | $514.36M | $19.13M |
| Operating Cash Flow | $-31.16M | $36.76M | $66.49M | $39.95M | $46.48M | $65.25M | $84.63M | $42.17M | $51.78M | $73.38M | $82.09M | $50.02M | $65.15M | $72.61M | $88.65M | $56.11M | $64.24M | $54.07M | $36.02M | $35.85M |
| Capital Expenditure | $- | $-18.45M | $-19.61M | $-19.81M | $-28.60M | $-29.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-31.16M | $18.31M | $46.88M | $20.14M | $17.89M | $35.75M | $84.63M | $42.17M | $51.78M | $73.38M | $82.09M | $50.02M | $65.15M | $72.61M | $88.65M | $56.11M | $64.24M | $54.07M | $36.02M | $35.85M |
SITE Centers Dividends
Explore SITE Centers's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
15.98%
Dividend Payout Ratio
24.08%
Dividend Paid & Capex Coverage Ratio
0.87x
SITE Centers Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.13 | $0.52 | June 18, 2024 | June 18, 2024 | July 09, 2024 | May 08, 2024 |
| $0.13 | $0.52 | March 13, 2024 | March 14, 2024 | April 05, 2024 | February 13, 2024 |
| $0.16 | $0.64 | December 26, 2023 | December 27, 2023 | January 12, 2024 | December 13, 2023 |
| $0.13 | $0.52 | December 08, 2023 | December 11, 2023 | January 05, 2024 | October 30, 2023 |
| $0.13 | $0.52 | September 25, 2023 | September 26, 2023 | October 12, 2023 | September 13, 2023 |
| $0.13 | $0.52 | June 13, 2023 | June 14, 2023 | July 06, 2023 | May 10, 2023 |
| $0.13 | $0.52 | March 16, 2023 | March 17, 2023 | April 06, 2023 | February 14, 2023 |
| $0.0325 | $0.13 | December 08, 2022 | December 09, 2022 | January 06, 2023 | November 01, 2022 |
| $0.13 | $0.52 | September 19, 2022 | September 20, 2022 | October 07, 2022 | September 07, 2022 |
| $0.13 | $0.52 | June 08, 2022 | June 09, 2022 | July 06, 2022 | May 11, 2022 |
| $0.0325 | $0.13 | March 16, 2022 | March 17, 2022 | April 07, 2022 | February 10, 2022 |
| $0.12 | $0.48 | December 09, 2021 | December 10, 2021 | January 05, 2022 | November 03, 2021 |
| $0.12 | $0.48 | September 23, 2021 | September 24, 2021 | October 08, 2021 | September 09, 2021 |
| $0.12 | $0.48 | June 09, 2021 | June 10, 2021 | July 02, 2021 | May 11, 2021 |
| $0.0275 | $0.11 | March 17, 2021 | March 18, 2021 | April 06, 2021 | February 18, 2021 |
| $0.05 | $0.2 | December 10, 2020 | December 11, 2020 | January 07, 2021 | November 12, 2020 |
| $0.05 | $0.2 | March 09, 2020 | March 10, 2020 | April 02, 2020 | February 12, 2020 |
| $0.05 | $0.2 | December 12, 2019 | December 13, 2019 | January 07, 2020 | November 07, 2019 |
| $0.05 | $0.2 | September 20, 2019 | September 23, 2019 | October 08, 2019 | September 11, 2019 |
| $0.2 | $0.8 | June 11, 2019 | June 12, 2019 | July 02, 2019 | May 09, 2019 |
SITE Centers News
Read the latest news about SITE Centers, including recent articles, headlines, and updates.
SITE Centers: Cost Control Key After Curbline Properties Spin-Off
SITE Centers is a retail REIT focused on open-air shopping centers in high-income communities. The REIT's Q4 2024 results show it is slow to adapt general and administrative expenses to a much smaller asset base. I compare SITC's administrative overhead to Simon Property Group, showing room for substantial improvement.
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting
SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14.
Dividend Power Dogs: 3 Top Dividend Picks For March
Three top Dividend Power stocks, Golden Ocean, Diversified Energy, and Saratoga Investment Corp, offer "safer" dividends with free cash-flow yields exceeding dividend yields. The Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, creating a resilient portfolio for both downturns and bull markets. Analysts predict significant net gains (39.97% to 168.6%) for the top ten Dividend Power stocks by March 2026, with an average net gain of 77.96%.
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. Details of the poster presentation are as follows: Abstract Ti.
Here's What Key Metrics Tell Us About SITE Centers Corp. (SITC) Q4 Earnings
The headline numbers for SITE Centers Corp. (SITC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. Details for the presentation are as follows: Abstract Number: 123 Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute Date & Time: Wednesday, March 12, 2025 at 5:10 p.m.
69 Graham Value All-Stars, Of 20 'Safer' Choices, Buy Any Of 14
The Value Score identifies large-cap stocks offering the best value relative to their assets and profits, focusing on low-priced, high-value investments. The Ben Graham Formula targets ultra-stable stocks with strong earnings, dividends, and low valuations, ensuring long-term stability and minimal losses. Analysts forecast significant gains (29.57% to 79.74%) for top-ten GASV stocks by January 2026, highlighting high-yield, low-risk investment opportunities.
4 Of 35 Safe-Buy Dividend Power Dogs In January
Four low-priced Dividend Power stocks, Golden Ocean, Invesco Mortgage, ARMOUR Residential, and FutureFuel, offer safer dividends with free cash-flow yields exceeding dividend yields. The Dividend Power strategy focuses on high earnings yield and top dividend yield stocks, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for top Dividend Power stocks, with an average net gain of 79.97% on $10k invested in the top ten.
Of 36 Dividend Power Dogs, 11 Are Buyable In November
Eleven of the 35 Dividend Power Dogs are recommended for their "safer" dividends, with free cash-flow yields exceeding dividend yields, making them ideal buys. The Dividend Power strategy focuses on high earnings yield and high dividend yield, creating a resilient portfolio for both downturns and bull markets. Analysts project significant gains for the top ten DiviPower stocks by November 2025, with potential net gains ranging from 55.4% to 108.51%.
CBL & Associates Properties Vs. SITE Centers: Which Is The Better REIT For 2025
CBL & Associates Properties and SITE Centers are REITs focused on retail real estate, with reported occupancy rates indicating poor competitive dynamics. CBL funds a greater proportion of its capital structure with debt, but both companies have significant floating rate debt exposure. CBL is more attractively valued on an enterprise-level and AFFO multiple basis, but also reports higher administrative expenses.
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025 SAN JOSE, Calif. , Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (NCT04674306) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas.
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody” at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, from November 6-10, 2024 in Houston, TX.
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where it is conditionally activated by tumor-associated proteases
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-BRES+™ and Bria-PROS+™, respectively, during a poster session at the 2024 Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET® will be presented at the SITC Annual Meeting 2024. “We are thrilled to share our latest preclinical data at the SITC Annual Meeting, highlighting the potential of IPH6501, our tetra-spe.
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
HONG KONG , Nov. 7, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47.
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens
Strong Evidence of AU-007's Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 dose escalation and cohort expansion study of AU-007. The data will be presented in a poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston, Texas. Preliminary Phase 2 data reveal that a combination of AU-007 and low-dose,.
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 – – Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation – SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. NKTR-255 is a novel polymer-conjugated IL-15 agonist, designed to activate, proliferate and expand natural killer (NK) and CD8+ T-cells, as well as to promote the survival and expansion of memory CD8+ T cells.
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade -
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for SITC.